Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Adaptimmune Therapeutics plc. (5/10/17). "Press Release: Adaptimmune Reports First Quarter 2017 Financial Results". Philadeliphia, PA & Oxford.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 Matrix Capital Management Company L.P.
  Group Matrix Capital (Group)
Products Product AFP SPEAR™ T-cell therapy
  Product 2 letetresgene autoleucel (NY-ESO SPEAR® T-cell therapy)
Index term Index term Adaptimmune–Matrix Capital Management: investment, 201704 direct offering $42m of 7m ADSs at $6/ADS
Persons Person Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
  Person 2 Tayton-Martin, Helen (Adaptimmune 201703– CBO before COO + Co-Founder before Avidex/Medigene)

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Adaptimmune (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top